A Phase 2 interventional study of Prexasertib in Ovarian Cancer, sponsored by Eli Lilly and Company. Completed at 46 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-19.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Ovarian Neoplasms by Eli Lilly and Company — 6 open to participants now, 9 under way, 1 of them phase 3. Ovarian Neoplasms · Eli Lilly and Company.
Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one is the 12th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 2, and was the 19th registered.
3,385 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →6 of the 29 studies in Ovarian Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 24 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, France and 6 more countries
Ages 18+
By country, each count listing its studies:
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 17 · Phase 3 3 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 158 across the 26 interventional studies. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 536 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
3 of the studies in Ovarian Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have at least one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
Drug: Prexasertib
Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received \<3 lines of prior therapy.
Drug: Prexasertib
Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
Drug: Prexasertib
Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
Drug: Prexasertib
Administered IV
Also known as: LY2606368
Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100.
Time frame: Baseline through Disease Progression (Up to 6 months)
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Prexasertib
Pharmacokinetics(PK): Maximum Plasma Concentration of Prexasertib. The same dose was administered to Cohort 1, 2, 3 and 4 and were combined for analysis.
Time frame: Cycle 1, Cycle 2, Cycle 4, Cycle 6 (Day 1 (End of prexasertib infusion (+15 min), 1-2 hours following end of prexasertib infusion), Cycle 2, day 1(Prior to start of prexasertib infusion)
Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD) for at Least 4 Months
DCR is defined as the number of participants who achieve a best overall response of CR, PR or SD for ≥4 months as determined by per RECIST version 1.1. CR is the disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion; SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Disease control rate is calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated, then multiplied by 100.
Time frame: Baseline through Disease Progression (up to 6 months)
Duration of Response
Duration of response is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment.
Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (up to 20 months)
Percentage of Participants With at Least a 50% Reduction in CA-125 Levels From Baseline
CA-125 response is defined as ≥50% reduction in CA-125 levels from a pretreatment sample. The response must be confirmed and maintained for ≥28 days according to GCIG criteria. Participants must have a pretreatment sample that is ≥2 times the upper limit of the reference range and obtained within 2 weeks before starting the treatment.
Time frame: Baseline, 4 Weeks
Progression-Free Survival
Progression-Free Survival (PFS) is defined as the time from the date of enrollment until the first occurrence of documented disease progression per RECIST 1.1, or death from any cause in the absence of progressive disease (PD). Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment.
Time frame: Baseline to Disease Progression or Death from any Cause (Up to 22 months)
Overall Survival
Overall survival (OS) is defined as the time from the date of enrollment until death from any cause. If the participant is alive, lost to follow-up or withdrawn from study at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
Time frame: Baseline to Date of Death from Any Cause (Up to 26 months)
Completers included participants who died from any cause and participants who were alive and on study (either on study treatment or in long term follow-up) at study conclusion.
| Milestone | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Started | 53 | 46 | 41 | 29 |
| Received at least one dose of study drug | 53 | 46 | 41 | 29 |
| Completed | 51 | 46 | 38 | 27 |
| Not completed | 2 | 0 | 3 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 0 |
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100.
| Percentage of Participants | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR) | 11.3 (4.3 to 23.0) | 13.0 (4.9 to 26.3) | 12.2 (4.1 to 26.2) | 6.9 (0.8 to 22.8) |
Pharmacokinetics(PK): Maximum Plasma Concentration of Prexasertib. The same dose was administered to Cohort 1, 2, 3 and 4 and were combined for analysis.
| nanograms per milliliter(ng/mL) | Prexasertib |
|---|---|
| Cycle 1 | 668 ± 50 |
| Cycle 2 | 718 ± 62 |
| Cycle 4 | 678 ± 61 |
| Cycle 6 | 672 ± 42 |
DCR is defined as the number of participants who achieve a best overall response of CR, PR or SD for ≥4 months as determined by per RECIST version 1.1. CR is the disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion; SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Disease control rate is calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated, then multiplied by 100.
| Percentage of participants | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD) for at Least 4 Months | 45.3 (31.6 to 59.6) | 32.6 (19.5 to 48.0) | 31.7 (18.1 to 48.1) | 31.0 (15.3 to 50.8) |
Duration of response is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment.
| Months | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Duration of Response | 8.57 (5.55 to NA) | 3.84 (2.79 to NA) | 5.55 (3.65 to 9.36) | 5.31 (5.06 to NA) |
CA-125 response is defined as ≥50% reduction in CA-125 levels from a pretreatment sample. The response must be confirmed and maintained for ≥28 days according to GCIG criteria. Participants must have a pretreatment sample that is ≥2 times the upper limit of the reference range and obtained within 2 weeks before starting the treatment.
| Percentage of participants | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Percentage of Participants With at Least a 50% Reduction in CA-125 Levels From Baseline | 39.6 | 34.8 | 17.1 | 37.9 |
Progression-Free Survival (PFS) is defined as the time from the date of enrollment until the first occurrence of documented disease progression per RECIST 1.1, or death from any cause in the absence of progressive disease (PD). Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment.
| Months | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Progression-Free Survival | 3.91 (3.68 to 5.68) | 3.71 (3.12 to 4.70) | 3.58 (1.87 to 3.91) | 3.71 (1.77 to 4.70) |
Overall survival (OS) is defined as the time from the date of enrollment until death from any cause. If the participant is alive, lost to follow-up or withdrawn from study at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
| Months | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Overall Survival | 13.04 (7.46 to 19.25) | 14.32 (11.76 to 16.46) | 11.14 (7.23 to 16.43) | 8.18 (6.18 to 11.93) |
Collected over Baseline, upto 26 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prexasertib Cohort 1 | 2/53 (3.8%) | 23/53 (43.4%) | 53/53 (100%) |
| Prexasertib Cohort 2 | 1/46 (2.2%) | 17/46 (37%) | 44/46 (95.7%) |
| Prexasertib Cohort 3 | 1/41 (2.4%) | 19/41 (46.3%) | 39/41 (95.1%) |
| Prexasertib Cohort 4 | 1/29 (3.4%) | 15/29 (51.7%) | 28/29 (96.6%) |
| Event | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 5/53 | 3/46 | 5/41 | 4/29 |
| PyrexiaGeneral disorders | 1/53 | 5/46 | 1/41 | 1/29 |
| VomitingGastrointestinal disorders | 1/53 | 4/46 | 1/41 | 3/29 |
| NeutropeniaBlood and lymphatic system disorders | 4/53 | 3/46 | 4/41 | 2/29 |
| AnaemiaBlood and lymphatic system disorders | 0/53 | 2/46 | 2/41 | 2/29 |
| Abdominal painGastrointestinal disorders | 0/53 | 1/46 | 1/41 | 2/29 |
| Small intestinal obstructionGastrointestinal disorders | 1/53 | 3/46 | 1/41 | 2/29 |
| PneumoniaInfections and infestations | 1/53 | 1/46 | 2/41 | 2/29 |
| SepsisInfections and infestations | 2/53 | 1/46 | 0/41 | 2/29 |
| Urinary tract infectionInfections and infestations | 1/53 | 3/46 | 0/41 | 1/29 |
| Event | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 19/53 | 24/46 | 15/41 | 16/29 |
| VomitingGastrointestinal disorders | 21/53 | 13/46 | 11/41 | 14/29 |
| AnaemiaBlood and lymphatic system disorders | 20/53 | 17/46 | 15/41 | 12/29 |
| FatigueGeneral disorders | 21/53 | 19/46 | 12/41 | 12/29 |
| Abdominal painGastrointestinal disorders | 14/53 | 18/46 | 11/41 | 10/29 |
| NeutropeniaBlood and lymphatic system disorders | 19/53 | 10/46 | 11/41 | 10/29 |
| DiarrhoeaGastrointestinal disorders | 19/53 | 15/46 | 7/41 | 8/29 |
| ThrombocytopeniaBlood and lymphatic system disorders | 17/53 | 14/46 | 14/41 | 7/29 |
| PyrexiaGeneral disorders | 13/53 | 5/46 | 7/41 | 8/29 |
| ConstipationGastrointestinal disorders | 13/53 | 12/46 | 8/41 | 5/29 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(Years) | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 | Total |
|---|---|---|---|---|---|
| Mean | 61.3 ± 9.4 | 62.3 ± 9.4 | 59.5 ± 8.6 | 59.0 ± 13.4 | 60.8 ± 10.0 |
| Sex: Female, Male(Participants) | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 53 | 46 | 41 | 29 | 169 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 0 | 0 | 4 |
| Not Hispanic or Latino | 48 | 40 | 39 | 28 | 155 |
| Unknown or Not Reported | 4 | 3 | 2 | 1 | 10 |
| Race (NIH/OMB)(Participants) | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 8 | 4 | 3 | 21 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 0 | 2 |
| Black or African American | 0 | 1 | 0 | 1 | 2 |
| White | 46 | 36 | 37 | 25 | 144 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Prexasertib Cohort 1 | Prexasertib Cohort 2 | Prexasertib Cohort 3 | Prexasertib Cohort 4 | Total |
|---|---|---|---|---|---|
| South Korea | 4 | 5 | 2 | 2 | 13 |
| Belgium | 4 | 1 | 3 | 0 | 8 |
| United States | 6 | 13 | 3 | 10 | 32 |
| United Kingdom | 6 | 9 | 4 | 1 | 20 |
| Italy | 4 | 4 | 8 | 7 | 23 |
| Israel | 6 | 3 | 7 | 4 | 20 |
| Australia | 14 | 7 | 10 | 3 | 34 |
| Spain | 9 | 4 | 4 | 2 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2018 to primary completion in Jun 2019, 13 months.
Results were first posted in Jun 2020, 1 year after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 13 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prexasertib